000			02051naaaa2200325uu 4500
001			https://directory.doabooks.org/handle/20.500.12854/40785
005			20220220084126.0
020			_a978-2-88919-443-8
020			_a9782889194438
024	7		_a10.3389/978-2-88919-443-8 _cdoi
041	0		_aEnglish
042			_adc
100	1		_aRobert Marr _4auth
700	1		_aEliezer Masliah _4auth
245	1	0	_aAmyloid-beta clearance in Alzheimer's disease
260			_bFrontiers Media SA _c2015
300			_a1 electronic resource (111 p.)
506	0		_aOpen Access _2star _fUnrestricted online access
520			_aStrong evidence continues to accumulate indicating that amyloid-beta (Aß) is a central part of Alzheimer’s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aß are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to Aß clearance in AD. The topics covered include proteases that degrade Aß and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed.
540			_aCreative Commons _fhttps://creativecommons.org/licenses/by/4.0/ _2cc _4https://creativecommons.org/licenses/by/4.0/
546			_aEnglish
653			_aamyloid-beta
653			_aSignal Transduction
653			_aProteases
653			_aLDL receptors
653			_aClearance
653			_aAlzheimer's disease
856	4	0	_awww.oapen.org _uhttp://journal.frontiersin.org/researchtopic/2235/amyloid-beta-clearance-in-alzheimers-disease _70 _zDOAB: download the publication
856	4	0	_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/40785 _70 _zDOAB: description of the publication
999			_c76547 _d76547